Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.
作者信息
Manosuthi Weerawat, Butler David M, Chantratita Wasun, Sukasem Chonlaphat, Richman Douglas D, Smith Davey M
出版信息
AIDS Res Hum Retroviruses. 2010 Jun;26(6):609-11. doi: 10.1089/aid.2009.0107.
Abstract
摘要
相似文献
1
Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.
AIDS Res Hum Retroviruses. 2010 Jun;26(6):609-11. doi: 10.1089/aid.2009.0107.
2
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Antivir Ther. 2011;16(7):1113-21. doi: 10.3851/IMP1906.
3
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
AIDS Res Hum Retroviruses. 2018 Aug;34(8):667-671. doi: 10.1089/AID.2017.0135. Epub 2018 Jun 12.
4
Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.
5
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.
6
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. doi: 10.1128/AAC.00986-09. Epub 2009 Nov 23.
7
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
AIDS. 2014 Sep 24;28(15):2331-2. doi: 10.1097/QAD.0000000000000350.
8
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
Antimicrob Agents Chemother. 2010 Apr;54(4):1596-602. doi: 10.1128/AAC.01480-09. Epub 2010 Feb 1.
9
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
J Antimicrob Chemother. 2010 Jul;65(7):1477-85. doi: 10.1093/jac/dkq140. Epub 2010 May 12.
10
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
J Antimicrob Chemother. 2015 Feb;70(2):562-5. doi: 10.1093/jac/dku395. Epub 2014 Oct 25.
引用本文的文献
1
Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes.
Open Forum Infect Dis. 2015 Nov 3;3(2):ofv158. doi: 10.1093/ofid/ofv158. eCollection 2016 Apr.
2
High prevalence of PI resistance in patients failing second-line ART in Vietnam.
J Antimicrob Chemother. 2016 Mar;71(3):762-74. doi: 10.1093/jac/dkv385. Epub 2015 Dec 11.
3
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.
Scientifica (Cairo). 2012;2012:238278. doi: 10.6064/2012/238278. Epub 2012 Dec 31.
4
Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-line antiretroviral therapy by WHO 2010 guidelines.
AIDS Res Hum Retroviruses. 2013 Jul;29(7):985-92. doi: 10.1089/aid.2013.0025. Epub 2013 Apr 27.
5
The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
PLoS One. 2013;8(2):e54435. doi: 10.1371/journal.pone.0054435. Epub 2013 Feb 15.
6
Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.
Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8. doi: 10.1128/AAC.00591-12. Epub 2012 Jun 25.
7
Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations.
AIDS Res Hum Retroviruses. 2012 Dec;28(12):1763-5. doi: 10.1089/AID.2011.0331. Epub 2012 May 21.
8
Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.
9
Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.
AIDS. 2011 May 15;25(8):1123-6. doi: 10.1097/QAD.0b013e328346269f.
10
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.
Antimicrob Agents Chemother. 2011 Feb;55(2):600-7. doi: 10.1128/AAC.01192-10. Epub 2010 Dec 6.
本文引用的文献
1
Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1.
Clin Infect Dis. 2009 May 1;48(9):1306-9. doi: 10.1086/598503.
2
Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008.
J Med Assoc Thai. 2008 Dec;91(12):1925-35.
3
Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.
AIDS Rev. 2008 Oct-Dec;10(4):212-23.
4
Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
Curr HIV Res. 2008 Sep;6(5):474-6. doi: 10.2174/157016208785861230.
5
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.
6
7
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
J Antimicrob Chemother. 2008 Nov;62(5):909-13. doi: 10.1093/jac/dkn297. Epub 2008 Jul 23.
8
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Clin Infect Dis. 2008 Jul 15;47(2):266-85. doi: 10.1086/589297.
9
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet. 2007 Jul 7;370(9581):39-48. doi: 10.1016/S0140-6736(07)61048-4.
10
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet. 2007 Jul 7;370(9581):29-38. doi: 10.1016/S0140-6736(07)61047-2.
Zotero 插件